Publications by authors named "F T Roncolato"
Article Synopsis
- Researchers studied how well patients with stage 1 testicular cancer kept up with their doctor's appointments from 2005 to 2023.
- Out of 125 patients, 51% followed their appointments well, while 38% didn't come back at all.
- Factors like not smoking, having a partner, and being from diverse backgrounds helped patients stick to their appointments more.
Article Synopsis
- The study aims to assess the baseline symptom burden experienced by patients with recurrent ovarian cancer and its relationship with progression-free survival and overall survival.
- Analysis involved 948 patients with either platinum-resistant or potentially platinum-sensitive recurrent ovarian cancer receiving advanced chemotherapy, revealing that a significant majority experienced mild to severe symptoms, including pain, fatigue, and anxiety.
- Results showed that higher symptom burden was linked to reduced progression-free survival and overall survival, highlighting the need for effective symptom management in clinical settings and trials.
Article Synopsis
- Some cancer patients think their treatments will cure them or give them more time to live, but many are not really clear about their actual chances.
- Researchers talked to 104 patients and their doctors to see how they view the benefits of their cancer treatments.
- They found that a lot of patients expect their treatments to help them more than their doctors believe it will, especially when it comes to quality of life versus length of life.
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.
Best Pract Res Clin Haematol
December 2023
The bone marrow failure syndromes (BMFS) are a diverse group of acquired and inherited diseases which may manifest in cytopenias, haematological malignancy and/or syndromic multisystem disease. Patients with BMFS frequently experience poor outcomes, and improved treatment strategies are needed. Collation of clinical characteristics and patient outcomes in a national disease-specific registry represents a powerful tool to identify areas of need and support clinical and research collaboration.
View Article and Find Full Text PDFArticle Synopsis
- * The study, which took place at 49 centers in Australia, China, South Korea, and the USA, included 104 patients who met eligibility criteria and received the medication at a daily dose of 150 mg until disease progression.
- * Results showed that 88 patients were included in the primary analysis, with a median follow-up of 13.3 months, highlighting the drug's potential effectiveness in treating this challenging cancer type.